Sinopharm mulls $1B buy­out of Chi­na-based DNA syn­the­sis com­pa­ny — re­port

Af­ter spend­ing the last cou­ple of years laser-fo­cused on its in­ac­ti­vat­ed Covid-19 vac­cine, Sinopharm is re­port­ed­ly in the mar­ket to ex­pand its DNA syn­the­sis ca­pa­bil­i­ties — and it may be will­ing to pay a pret­ty pen­ny.

Sinopharm is con­sid­er­ing a $1 bil­lion-plus deal to snap up Chi­na-based BBI Life Sci­ences, un­named sources told Bloomberg. The com­pa­ny has re­port­ed­ly been in talks with the Wang fam­i­ly, who found­ed BBI back in 2013.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER